Conclusions. The maternofetal outcomes in patients with kidney transplantation are comparable with those of nontransplanted CKD patients with similar levels of kidney function impairment and progressive and/or immunologic kidney disease.
(Transplantation 2017;101: 2536-2544)
A mong the many advantages of kidney transplantation over dialysis, pregnancy is of particular relevance for young patients, and successful delivery after transplantation is considered by patients and physicians as one of the main achievements of this therapy. [1] [2] [3] [4] According to a recent in-depth systematic review that includes over 4700 transplanted patients, post-KT pregnancy is feasible, but complication rates are still relatively high as compared with the general population in the United States. 5 The reasons for this are not fully understood: the presence of impaired renal function, hypertension, and proteinuria were identified as important determinants of the outcomes, [6] [7] [8] [9] [10] as were interval between transplantation and pregnancy, 5, 11, 12 maternal age, 4, 5 and immunosuppressive drugs. 1, [13] [14] [15] Although it may be intuitive that patients with a transplanted kidney and impaired renal function are at higher risk for adverse pregnancy-related outcomes, as is extensively described in nontransplanted patients with chronic kidney disease (CKD), the degree of risk has never been fully assessed. [16] [17] [18] [19] [20] This is also due to the high heterogeneity of the study populations and of the controls, as well as to the lack of common terminology and of reliable measurements of kidney function in both physiological pregnancies and in pregnancies complicated by preeclampsia (PE) or kidney disease. 10, [21] [22] [23] [24] [25] [26] One of the effects of CKD reclassification in the new millennium was to focus attention on various situations, including pregnancy, in the early stages of the disease. 16, 17, [27] [28] [29] [30] [31] Changes in the definition of CKD went hand in hand with the progress being made in maternal-fetal medicine and neonatal care, which included anticipated the timing of "viable" delivery, whereas the new therapies allowed the indications for kidney transplantation to be further broadened. [32] [33] [34] [35] [36] The new millennium is also the era of patient empowerment, making way for counseling in delicate situations, such as pregnancy in CKD or after kidney transplantation. [37] [38] [39] [40] The aim of this collaborative study was to analyze the risks for adverse pregnancy-related outcomes in the new millennium in a nationwide Italian cohort of kidney transplant patients and to compare the data to a large multicenter cohort of CKD patients and low-risk pregnancies using the data from the 2014 update of the Torino-Cagliari Observational Study on CKD and pregnancy (TOCOS) and applying the stratification criteria previously established in CKD. 41 The results of such a comparison may cast light on the weight of immunosuppressive therapies and of renal function derangements in determining pregnancy outcomes in KT and CKD patients.
MATERIALS AND METHODS

Data Sources
The present study was planned in the context of the activities of the Study group on "Kidney and Pregnancy" of the Italian Society of Nephrology. In the absence of registry data on pregnancy after renal transplantation, the present analysis was based on systematic phone interviews and e-mail contacts with all the Italian transplant Centers. The study database we built will be the basis for a prospective update.
By June 2014, answers had been obtained from 24 of 37 kidney transplant centers that were active on December 2013. Based on the data of the Italian Regions with fully updated archives, we estimated that the survey covers about 75% of the Italian kidney transplant population. The database includes data on pregnancies that have been reported since 1978; however, due to differences recorded over time in obstetrics, only deliveries as of January 1, 2000, were included in the present analysis. 42 Data regarding CKD patients and low-risk controls were obtained from the 2014 update of the TOCOS database, described in detail elsewhere. 41 At December 2014, after excluding pregnancies in dialysis or after kidney transplantation, the TOCOS cohort consisted of 610 live-born singletons from CKD mothers and 1418 low-risk live-born singleton deliveries.
Selection Criteria
We decided to focus on the more robust data of live-born babies because these data are less subject to reporting biases, which are common in retrospective analyses, considering also that the definitions of intrauterine death, abortion, and perinatal death may be difficult to interpret and may overlap, an important issue in international comparisons because it is also encountered in pregnancies in dialysis patients. 21, 43, 44 Consequently, data on intrauterine deaths and abortions (pregnancy losses <24 gestational weeks) were collected but not included in the present analysis.
Collected Data
The following information was retrieved whenever appropriate in CKD and kidney transplant pregnancies: general data and maternal information: name (code), center, date of birth, date of renal replacement therapy start, data of kidney transplant, type of kidney transplant (cadaveric, living donor), maternal age at the start of pregnancy, type of kidney disease, functional data (serum creatinine, e-GFR calculated by CKD-EPI formula on account of its widespread use, 45 blood pressure, anti-hypertensive medications) at the start of pregnancy and at delivery. Proteinuria (24-hour urine collection) was not included in the original survey in transplant patients and was available only for CKD subjects; a followup call to all transplant centers showed that these data were not available before or at the start of pregnancy for over 70% of patients, thus leading to our decision not to include proteinuria in the present analysis.
Information on gestation and delivery: gestational week at delivery, birth weight, centile (according to the Italian reference Parazzini charts, the reference in the period of study 46 ), Apgar score, weight, sex, major malformations; follow-up of the mother (alive, in conservative treatment, on dialysis, functioning kidney graft) and of the child; in case of death, date and cause death. The main maternal problems in pregnancy were also recorded.
Definitions
Causes of end-stage kidney disease were classified into broad categories: glomerulonephritis and systemic immunologic diseases, interstitial nephropathy and chronic pyelonephritis, diabetic nephropathy, polycystic kidney disease, other unknown. In the CKD population, 2 further categories were considered: persistent urinary anomalies and previous pyelonephritis with kidney scars. Furthermore, a subset which includes diabetic nephropathy, glomerulonephritides, and systemic diseases was defined as "potentially progressive CKD."
Hypertension was defined as systolic blood pressure of 140 mm Hg or greater and/or diastolic blood pressure of 90 mm Hg or greater, or antihypertensive therapy; patients on antihypertensive therapy before conception were considered hypertensive even when antihypertensive therapy was discontinued in early pregnancy.
PE was defined by using the classic definition of hypertension accompanied by proteinuria ≥300 mg/24 hours after 20 weeks of gestational age in a previously normotensive, nonproteinuric woman, in the absence of other signs or symptoms indicating a different nephrological diagnosis; Doppler flow alterations were considered further support PE diagnosis. This strict diagnosis applies only to subjects who were normotensive and nonproteinuric; because the definition of "superimposed PE" is not absolute, and because the overlap with CKD is higher, we did not include it in this study. 41, 47 Due to the characteristics of CKD and kidney transplant patients, we did not use the recent The American Congress of Obstetricians and Gynecologists definitions which also consider an increase in serum creatinine as diagnostic.
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A newborn was defined as small for gestational age (SGA) when the birth weight was below the fifth or 10th centile according to Italian birth weight references (Parazzini charts   46 ); again, this is not an absolute definition, and although acknowledging its limits, we chose the 2 most frequently used cutoff points, fifth and 10th centile. [49] [50] [51] [52] Preterm delivery was defined as delivery occurring before 37 completed gestational weeks; early preterm delivery as delivery occurring before 34 completed gestational weeks and extreme early preterm delivery as delivery occurring before 28 completed gestational weeks. 49, 53, 54 Statistical Analysis A descriptive analysis was performed as appropriate (mean and standard deviation for parametric data and median and range for nonparametric data). Independent t test, χ 2 test, Fisher test, and Mann-Whitney U test were used, where indicated, for comparisons between patients and controls and among groups. Significance was set at P less than 0.05.
Multiple regression analysis was performed considering the outcomes: preterm delivery, early preterm delivery, SGA baby, and the following covariates: age; CKD or kidney transplant; CKD stage at start of pregnancy; hypertension at start of pregnancy (SPSS version 18.0 for Windows, Chicago, IL).
Kaplan-Meier analysis was performed as time to event analysis, with observation going from the 24th week until the date of live-born delivery. The analysis was performed as implemented on SAS 9.2. Differences were assessed by Log-rank and Wilcoxon tests.
Study Design
First of all, the 2 patient populations of CKD and kidney transplant patients were compared as per baseline data; second, stratification according to CKD stage was performed in both subsets of patients. Third, the "potentially progressive" patients were selected from the large CKD stage 1 population for comparison with stage 1 kidney transplant patients. Low-risk controls were used to contextualize the results.
Ethical Issues
The observational study protocol was approved and supported by the Italian Society of Nephrology (Gruppo di Studio Rene e Gravidanza). The epidemiological and outcome study on CKD in pregnancy and the related low-risk controls was approved by the Ethics Committee of O.I.R.M.-Sant'Anna Hospital (protocollo di studio 11551/c28.2;Delibera n. 335 del 4/3/2011). The observational study on kidney transplantation was approved by the ethics committee of the San Luigi Gonzaga hospital of the University of Torino, Italy (nota prot. n. 11655 del 26/06/13-studio osservazionale pratica comitato etico n. 90/2013 Delibera n. 363 del 17/06/13).
The clinical and research activities being reported are consistent with the Principles of the Declaration of Istanbul as outlined in the Declaration of Istanbul on Organ Trafficking and Transplant Tourism.
RESULTS
Baseline Data
One hundred twenty-one pregnancies in KT patients resulting in a live-born singleton baby were compared with 610 deliveries in CKD patients; mean age of the mothers was significantly higher in KT patients and, as expected by the different clinical histories, KT patients were more often affected by glomerulonephritides and immunologic diseases as compared with CKD patients in whom less severe diseases, mainly interstitial nephropathies, were more often present (Table 1) .
These differences affect also the distribution of CKD stages (P < 0.001). Consequently, serum creatinine before pregnancy or at referral is almost twice as high in KT patients, and the prevalence of hypertension rises from 24.4% in CKD to 55.4% in KT pregnancies. The overall characteristics reflect the Italian KT population during the study period, with a low prevalence of preemptive and living donor transplantations and a high prevalence of calcineurin inhibitors and of steroid treatments, that, albeit at low doses, are usually used in patients with immunologic diseases who make up the majority of KT subjects (Table 1) .
Despite the higher age, grafted patients were more often primigravidae, as compared with the CKD and low-risk population ( Table 1, Table 2 ). This finding may be explained by the long waiting time for transplantation: in fact, only a minority of cases was transplanted preemptively (5%) or received a living donor graft (14.9%).
The main immunodepressive medications were steroids, used in 90% of the cases, and calcineurin inhibitors (cyclosporine A in 51.7% and tacrolimus in 40.8%); Azathyoprine was used in 35% of the cases, resulting in 10 different drug combinations (Table S1 , SDC, http://links.lww.com/TP/B390). No difference according to the main calcineurin inhibitor was found in the logistic regression analysis (Table S2 , SDC, http://links.lww.com/TP/B390).
Main Outcomes and Outcomes Across CKD Stages
Given the baseline differences, timing of delivery is not surprisingly significantly different between KT and CKT patients, and in both situations versus low-risk pregnancies (P < 0.0001) (Figure 1 ). Table 2 , shows an increase of incidence of preterm delivery and early preterm delivery across functional stages, significant in CKD patients (χ 2 P <0.05), but not reaching significance in the smaller KT cohort.
Stratification for CKD stage, which is reported in
The KT cohort is characterized by a higher incidence of caesarean sections (CS) across all CKD stages. The pattern suggests a widespread policy of CS in KT patients, regardless of stage and comorbidity, to be further addressed in dedicated analyses.
With the exception of cesarean sections, the comparison between KT and CKD highlighted a substantial equivalence of the outcomes in stage 2 and in stages 3 to 5 patients that were taken into consideration, as also shown in Figure 2 which depicts centile distribution and age at birth in male and female babies born to CKD and KT patients in CKD stages 3, 4, 5.
However, in stage 1 patients, preterm, early, and extremely preterm deliveries, as well as small for gestational age newborns, are significantly more common in KT patients (Table 2) . Due to the impossibility to clearly diagnose PE in the CKD population, this outcome was not considered; none of the patients with a kidney graft developed hemolysisis, elevated Table 3 , was performed for preterm delivery, early preterm delivery, and small for gestational age baby, whereas cesarean section was not analyzed, because of colinearity with KT; the analysis confirms the relevance of CKD stage (RR of 3.42 and 3.78 for early preterm and preterm deliveries, respectively) and of baseline hypertension (RR of 3.68 and 3.16 for early and preterm deliveries, respectively) but not of being a KT recipient versus being a CKD patient, even if differences may be offset by the small sample size.
Furthermore, the multivariate analysis confirms the significant effect of parity on early preterm delivery (but not on preterm delivery an SGA); adding parity to the model does not affect the equivalence between KT and CKD (Table 3) . On account of the high heterogeneity of the CKD population, by including patients with a single kidney scar as well as patients with systemic, potentially progressive diseases, such as glomerulonephritis or diabetic nephropathy, a further comparison was carried out on patients with "potentially progressive" CKD. All patients were also compared with low-risk controls (Tables 4-5, Figures 3-4) .
Although all subsets of stage 1 patients differ from the lowrisk controls with regard to most or all of the outcomes we considered, the differences between KT and CKD pregnancies disappear if only "potentially progressive" diseases are considered (Table 4) . Timing of delivery and the distribution of weight according to gestational week at delivery follow the same distribution in these 2 subsets (Figures 3-4) .
Hypertension was confirmed as a significant outcome modulator by logistic regression analysis, whereas parity or being a KT or CKD patient had no effect on the outcomes (Table 5) .
DISCUSSION
Pregnancy is a great achievement for many women with chronic kidney disease before or after the start of renal replacement therapy; the decision to undertake a pregnancy may be FIGURE 1. Gestational age at delivery in low-risk controls, kidney transplant patients and CKD patients. FIGURE 2. Gestational age at delivery in low-risk controls, kidney transplant patients, and stage 1 CKD patients with "potentially progressive" disease.
extremely difficult, and the communication of medical risks should be balanced by respect of life priorities. 37, 55, 56 Risk assessment on which counseling is based usually considers pregnancy outcomes in the overall population or in low-risk pregnancies. 5, 6, 17, 26 The aim of the present study is to offer some insight into a complementary point of view: the patients' risks throughout their disease evolution, from CKD to KT. Our data show that the risk for 2 of the main pregnancy-related outcomes are similar in patients with comparable degrees of renal function impairment, in the pre-end-stage renal disease (ESRD) phase or after KT, and are modulated by the presence of hypertension (Tables 2-3 , Figures 1-2) .
Although the highly heterogeneous group of stage 1 CKD patients has overall better outcomes than KT patients, the differences disappear when only patients with "potentially progressive disease" are selected from among the large subset of stage 1 CKD patients. This is probably due to the fact that in our CKD cohort, there is a high prevalence of interstitial diseases, with normal renal function, no hypertension, and no proteinuria. Hence, we selected subjects with "potentially progressive disease," more similar to KT patients, in whom the immunological challenges and the reduced nephron mass make progression over time almost the rule (Tables 4-5 , Figures 3-4) .
From the physiopathologic point of view, our data suggest that once kidney function impairment is present, it represents a major determinant of the outcomes, thus offsetting the influence of therapy and of type of disease, and underlining the importance of the functioning nephron mass, as already reported in CKD patients. 19, 20, 30, 41 Conversely, the results observed in patients with normal kidney function may support either the role of the nephron mass (since patients with "potentially progressive" CKD may be in the "gray area" in which a substantial parenchymal reduction is not detected by conventional renal functional tests), or the role of the immunologic challenge shared by glomerulonephritides, systemic diseases and KT. The latter explanation is in line with the immunological hypothesis of the pathogenesis of PE and related hypertensive disorders of pregnancy, whose role in the development of adverse outcomes in CKD is only partially understood. [57] [58] [59] [60] From the clinical point of view, our data may add support to the counseling of both nontransplanted CKD and KT patients. In fact, in the past, non-KT patients with advanced CKD were often discouraged from undertaking pregnancy, although in some cases they were told that their chances could be improved by a successful KT. 40, [61] [62] [63] However, the conditions that were classically considered "safe" for pregnancy following KT identified only a subset of "best patients" (1-2 years after KT, good real function, no or low-grade proteinuria normotension). In both conditions, therefore, a gray area encompassed the patients with severe renal functional reduction. [61] [62] [63] [64] [65] [66] The great advances in pregnancy on dialysis have led to a paradigm shift; the increasingly good results with extended dialysis reduce the fear that the need to start or restart dialysis in pregnancy will invariably lead to adverse outcomes. 39, 44, [67] [68] [69] [70] Consequently, we may also expect an increase in patients with advanced CKD before or after KT who want to have a baby, in particular when increasing maternal age leads the patients to consider age-related subfertility.
The demonstration that the risk of adverse pregnancy outcomes for KT patients is similar to that of nontransplanted CKD patients with a corresponding degree of kidney function impairment and hypertensive status, should reassure KT patients about the lack of detrimental effects of their immunosuppressive therapy, at least on "macroevents," such as delivery of a small for gestational age, preterm baby (Tables 3-5) . Further, our study suggests that the broad creatinine-based categories that are used to distinguish highrisk and low-risk KT pregnancies should be broken down into more precise staging (Table 2) . Our observation of similar risks in CKD and KT patients may support undertaking pregnancy in the pre-ESRD stage, at least in patients without a living donor, given the long waiting lists, the impossibility to foresee kidney function after KT and the consideration that increasing maternal age is associated not only with fertility reduction but also with an increase in adverse pregnancy-related outcomes. 71, 72 Although ours is a novel study, it has several limitations, partly shared by other studies on pregnancy in CKD or after KT. 5, 16, 21, 44 Relatively large numbers became small after stratification, thus reducing the statistical power.
The databases are heterogeneous. Although data on CKD patients were gathered prospectively, the database on KT was the result of a retrospective inquiry, and reporting biases cannot be completely ruled out. Therefore, we hope that the data here discussed may raise attention and lead to running further large prospective studies on these issues.
Although no GFR formula is devoid of biases, errors may increase in pregnancy after KT, considering also that CNIs may cause a decrease in GFR (however measured) with an indirect effect on outcome. 24, 25, 29, 31, 45, [73] [74] [75] However, a common, simple assessment, as the CKD-EPI formula, chosen for its wide diffusion, is probably at present the only way to carry out clinical comparisons.
Considering the importance of proteinuria in pregnancyrelated outcomes, a major bias is the absence of this information in our database; this was due to lack of sufficient information in the original clinical charts, probably because attention to kidney function assessment and 24-hour proteinuria is only relatively recent in this setting (and patients with relevant proteinuria were probably often discouraged from undertaking pregnancy). The data have been added to the prospective database for future studies, once more stressing the need for new, detailed, and sharable information to support counseling and manage pregnancies in KT and CKD patients. Caesarean sections were more common in KT patients, in all stages; this pattern may suggest a policy preferring a priori this mode of delivery in KT patients, but this important issue should be assessed by dedicated analyses.
Lastly, we do not have data on assisted fertilization techniques in our CKD and KT populations (low-risk cases are by definitions spontaneous pregnancies). This item was added in the prospective database; however, because in Italy, until recently, the access to assisted fertilization techniques was limited to cases without comorbidity, the role of in vitro fertilization was probably negligible in the present study population.
In summary, the present study, based on a large multicenter cohort of pregnancies in KT patients whose data were compared to nontransplanted CKD and low-risk pregnancies, suggests that the patterns observed in KT closely correspond to those observed in nontransplanted CKD with a comparable degree of kidney function impairment or with normal renal function and "potentially progressive" disease.
These findings, reassuring on lack of a clear detrimental effect of immunosuppressive treatments, stress the importance of kidney function and hypertension as determinants of pregnancy-related outcomes and suggest the need for more detailed stratification of kidney function for risk assessment after KT. They also confirm that the differences versus the low-risk population are also observed in patients with normal renal function and may support the usefulness of tailoring counseling on the various phases of CKD.
